The appointment is part of the company’s strategy to develop into a so-called “bionic company”, with artificial intelligence to be broadly integrated across the organization.
According to Lundbeck, AI is expected to transform the way the company operates across the entire value chain, from research and early drug development to commercial operations and patient support.
BREAKING